Saturday, August 13, 2016 5:29:19 PM
Clearly they have inside info relating to their joint products with MNTA, included, but not limited to patent office expectations, Glatopa acceptance and sales, 40 mg likelihood of FDA approval. To sell now suggests a bit of urgency. While the optimists are hoping for good news later this month, which if it were to occur would suggest a slight bump at least in the stock price, selling now appears to make no sense. I can understand the registration to sell so NVS could take advantage of a major pop, but selling shares already suggests that is not their intent or expectation. They certainly are in no need for cash as $55 million has to be chump change for them.
Trying to figure out why now. Could NVS be planning to spin off Sandoz and wants to clean its books of any Sandoz partner holdings prior to a spinoff? Just wildly speculating.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM